#nasdaq:eglt

[marketexclusive]

Egalet Corp (NASDAQ:EGLT) Gets Approval But Fails On Labelling, Here's What's Next

Egalet Corp (NASDAQ:EGLT) Gets Approval But Fails On Labelling, Here’s What’s Next

Here is an interesting one. We have covered Egalet Corp (NASDAQ:EGLT) on a number of occasions in the past here at Market Exclusive, with a specific focus on its abuse deterrent opioid application, which has been with the FDA for the better part of 12 months in its latest iteration. The company has repeatedly tried to get the asset approved and advanced into the commercialization phase, but has…

View On WordPress

[marketexclusive]

Analyst Activity – Cantor Fitzgerald Reiterates Buy on Egalet Corp. (NASDAQ:EGLT)

Analyst Activity – Cantor Fitzgerald Reiterates Buy on Egalet Corp. (NASDAQ:EGLT)

Analyst Ratings For Egalet Corp. (NASDAQ:EGLT) Today, Cantor Fitzgerald reiterated its Buy rating on Egalet Corp. (NASDAQ:EGLT) with a price target of $21.00. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Egalet Corp. (NASDAQ:EGLT) is Buy (Score: 2.67) with a consensus target price of $12.83 per share, a potential 55.74% upside. Some recent analyst ratings…

View On WordPress

[marketexclusive]

Analyst Activity – Goldman Sachs Group Inc. Raises Its Price Target On Cairn Energy PLC (LON:CNE) to GBX 236.20

Analyst Activity – Goldman Sachs Group Inc. Raises Its Price Target On Cairn Energy PLC (LON:CNE) to GBX 236.20

Analyst Ratings For Cairn Energy PLC (LON:CNE) Today, Goldman Sachs Group Inc. raised its price target on Cairn Energy PLC (LON:CNE) to GBX 236.20 per share. There are 12 hold ratings, 8 buy ratings on the stock. The current consensus rating on Cairn Energy PLC (LON:CNE) is Hold (Score: 2.40) with a consensus target price of GBX 220.40 per share, a potential . Some recent analyst ratings include…

View On WordPress

[marketexclusive]

Egalet Corporation (NASDAQ:EGLT) Files An 8-K

Egalet Corporation (NASDAQ:EGLT) Files An 8-K

Egalet Corporation (NASDAQ:EGLT), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that the U.S. Food and Drug Administration (FDA) will not meet the previously announced October 14 prescription drug user fee act (PDUFA) date for ARYMO™ ER (morphine sulfate). “Today we…

View On WordPress

[twobeeinformed]

Horizon Pharma plc to Participate in Three Investor Conferences in February

Horizon Pharma plc to Participate in Three Investor Conferences in February

Horizon Pharma plc to Participate in Three Investor Conferences in February

View On WordPress